The country of origin of INFLECTRA® for Injection
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the processing of the active ingredient (made in South Korea) with excipients into 100 mg vials in dosage form in Portugal does not result in a substantial transformation and the country of origin will be South Korea.
Ruling text
In your letter dated July 4, 2025, you requested a country of origin ruling on INFLECTRA® (infliximab-dyyb) for Injection, for intravenous use. INFLECTRA® (Infliximab-dyyb) for Injection, imported in 100 mg vials, is a biologic treatment called a biosimilar that contains the active ingredient, Infliximab-dyyb.
The active pharmaceutical ingredient (API), Infliximab-dyyb is a chimeric IgG1 monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNF). Inflectra is a tumor necrosis factor (TNF) blocker that is administered via intravenous (IV) infusion for the treatment of Crohn’s Disease; Pediatric Crohn’s Disease; Ulcerative Colitis; Pediatric Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis; and Plaque Psoriasis.
In your letter, you requested a country of origin determination and indicated the active pharmaceutical ingredient (API) is also known as the drug substance (DS). You stated that the API or DS, is manufactured in South Korea and that the finished vials in dosage form are made in Portugal. In Portugal, the API (Infliximab-dyyb) will be formulated and combined with excipients, filled into vials and lyophilized into powder form to produce the final dosage drug called “unlabeled drug product (uDP)” in 100 mg vials.
Subsequently, the uDP in 100 mg vials are imported into the United States for labeling and packaging into the finished drug product (fDP) in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
In this case, we find the processing of the active ingredient (made in South Korea) with excipients into 100 mg vials in dosage form in Portugal does not result in a substantial transformation and the country of origin will be South Korea. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N350938).